Myelopoietins comprise a class of chimeric cytokine receptor agonists consisting of an hIL-3 (human interleukin-3) receptor agonist and an hG-CSF (human granulocyte colony-stimulating factor) receptor agonist linked head-to-tail at their respective carboxy and amino termini. The combination of an early acting cytokine (hIL-3) with a late acting one (hG-CSF) allows efficient hematopoeitic reconstruction following myeloablative insult, and drives differentiation of non-myelocytic lineages (ie thrombocytic lineages) that are inaccessible using hG-CSF alone, in both preclinical models and clinical settings. A myelopoietin species was displayed and mutagenized on filamentous bacteriophage: both component agonists of myelopoietin were presented in biologically functional conformations as each recognized its corresponding receptor. Five amino acid positions in a short region of the hG-CSF receptor agonist module of myelopoietin that had been identified as important for proliferative activity were mutagenized. Display was used because it allows very 'deep' mutagenesis at selected residues: Ͼ10 5 substitution variants were affinity-screened using the hG-CSF receptor and 130 new, active variants of myelopoietin were identified and characterized. None of the selected variants were significantly more active than the parental myelopoietin species in a hG-CSF-dependent cell proliferation assay, though many were as active. Many of these relatively high-activity variants contained parental amino acids at several positions, suggesting the parental sequence may already be optimal at these positions for the assays used, and potentially accounting for the failure to identify enhanced bioactivity variants. Analysis of substitutions of high-activity variants complements and extends previous alanine scanning, and other genetic and biochemical data for hG-CSF variants. Leukemia (2001) 15, 1277-1285.
Introduction
Chimeric proteins combine multiple polypeptides that are not normally covalently linked into a single molecular entity in which each functional domain contributes to overall activity. They are constructed to enhance properties of an already use-ful protein by introducing a new functionality (eg tissue-targeting function linked to a cytotoxin) or exploiting synergistic effects of related activities in a single molecule.
The myelopoietins are chimeric hematopoeitic growth factors containing human interleukin-3 (hIL-3) and human granulocyte colony-stimulating factor (hG-CSF) receptor agonists, 1 cytokines which engage specific receptor complexes on the surfaces of hematopoeitic progenitor cells to drive proliferation and differentiation. [2] [3] [4] [5] [6] [7] [8] Myelopoietins exploit synergistic effects of hG-CSF and hIL-3 receptor agonists, 9 and alleviate neutropenia and thrombocytopenia in primates following myelosuppression. 1, 10 The myelopoietin species studied here 1 has desirable hematopoietic properties, as well as good expression, purification, stability, biodistribution, and pharmacokinetic properties. 1, 10 Our goal was to identify myelopoietin variants with enhanced proliferative activity for the neutrophil lineage through mutagenesis of the hG-CSF receptor agonist domain.
Many variant hIL-3 and hG-CSF receptor agonist sequences might be incorporated into chimeras, so a vast number of distinct myelopoietin species are possible. So many, in fact, that conventional mutagenic methods cannot survey a significant fraction of them, despite the fact that relatively few variants are likely to be better agonists than the parent. We used phage display mutagenesis as it allows survey of orders of magnitude more variants than conventional methods. [11] [12] [13] Several four-helical bundle proteins 2 have been presented on phage, [14] [15] [16] [17] [18] [19] though chimeras containing multiple cytokines have not. Still, if both chimera domains are presented in functional conformations, display mutagenesis should be applicable to myelopoietin. The approach avoids concern that desirable properties of protein variants might change when the individually engineered variants are re-introduced into a chimera.
For biologically produced proteins, if n amino acid positions are randomly mutagenized, then 20 n variant proteins are possible. Despite its high mutagenic throughput, in most display mutagenesis experiments, only three to five positions are mutagenized at once to allow a significant fraction of the possible variants to be screened. 11 Five positions implicated in agonist activity in the hG-CSF receptor agonist module of myelopoietin were mutagenized [20] [21] [22] [23] [24] [25] using redundant synthetic oligonucleotide cassettes. 26, 27 Display experiments efficiently mature affinity of presented ligands for a target, [11] [12] [13] though maximizing receptor affinity may not maximize cytokine potency. 28 Our screening approach did not restrict us to studying only the high affinity Leukemia variants [11] [12] [13] in downstream cell proliferation assays, to allow capture of other desirable variants.
Materials and methods

Recombinant DNA and phage manipulations and analysis
Recombinant plasmids were constructed using standard molecular biology methods. 29 Phage displaying myelopoietin variants were produced from 1-5 liter 2xYT cultures of Escherichia coli JM101 co-infected with phagemid and helper phage M13KO7 as described.
14 Phage were harvested from culture by centirfugation and purified by polyethylene glycol precipitation and ultracentrifugation as described for hIL-3-presenting phage particles derived from pMON26452. 14, 30 Gel electrophoretic analysis and Western analysis of myelopoietinpresenting phage were performed as described. 14 
Phage presentation of myelopoietin
The parental myelopoietin species used in this work was composed of an N-terminal hIL-3 receptor agonist domain (SC-63032) connected by a peptidic linker to a C-terminal hG-CSF receptor agonist domain, as previously described, 1 and was presented using pMON15970, a monovalent presentation vector derived from pMON26452.
14 A map of pMON15970 and the sequence of the mutagenized region of the parental myelopoietin species (see below) are shown in Figure 1 .
Mutagenic strategy
The structure of hG-CSF is typical of the four-helical bundle superfamily of proteins. 20 We have limited mutagenesis within the myelopoietin hG-CSF receptor agonist domain to residues between amino acids 39 and 53, a region that extends from the end of the A helix through the short 3 10 helix and a six amino acid alpha helix downstream of it. The region overlaps the putative site 1 receptor binding site of hG-CSF, [20] [21] [22] [23] [24] [25] and is important to the cell proliferative activity of hG-CSF. Neutralizing antibodies bind in this region of the protein, 25 and alanine substitution at several positions between amino acids 39 and 53 of hG-CSF compromise hG-CSF biological activity. [20] [21] [22] [23] [24] All mutagenesis in this study was performed in the context of the myelopoietin chimeric protein (hG-CSF receptor agonists linked to the carboxy terminus of an hIL-3 receptor agonist) presented on phage. Despite the fact that phage display methods can provide orders of magnitude greater throughput than conventional methods for screening protein variants, random mutagenesis by display is usually limited to three to five positions to allow screening of a significant fraction of the possible variants. We mutagenized five positions.
We refer to residues in the hG-CSF receptor agonist module of myelopoietin using the same amino acid residue numbering scheme as used for parental hG-CSF. [20] [21] [22] [23] [24] [25] Using that convention, within the putative receptor binding site 1 region of the hG-CSF receptor agonist module of myelopoietin, solvent accessible [20] [21] [22] [23] [24] [25] residues 40, 43, 44, 49 and 52 were chosen for mutagenesis (see Figure 1 ). Amino acid substitution at surface residues such as these are unlikely to produce global perturbations of the protein structure, 26 ,27 though structural and gen-
Figure 1
The monovalent display vector pMON15970 directs display of myelopoietin on phage surfaces. Selected restriction sites and their positions (in base pairs, bp) are shown on the restriction map. Selected genetic elements are indicated. Amp indicates an ampicillinresistance gene and the ColE1 and M13 origins of replication are indicated by ColE1 ori and M13 ori, respectively. Plac indicates the lac promotor, gIII signal encodes the signal peptide of the filamentous phage gene product III signal sequence. The constituent domains of the myelopoietin gene encoding the hIL-3 receptor agonist, the IgG2b linker peptide and hG-CSF receptor agonist, expressed as a continuous reading frame, are also indicated. Nucleotide sequence and amino acid sequence (specified by the three letter code) of the region of parental myelopoietin that was mutagenized (the BstXI to SacI segment of the hG-CSF receptor agonist module) is shown in the exploded view portion of the figure. The amino acid residue numbering scheme used for the hG-CSF receptor agonist module of presented myelopoietin is the same as that used for parental hG-CSF (Refs 20-25, see Materials and methods). Codon positions subjected to redundant oligonucleotide cassette mutagenesis are indicated by number.
etic data suggest the residues may be important to protein function.
19-25
Construction of a library of mutations in the h-GCSF domain of phage-presented myelopoietin
Mutagenesis at positions 40, 43, 44, 49 and 52 of the hG-CSF receptor agonist domain of myelopoietin was performed using redundant, synthetic oligonucleotide cassettes. Oligonucleotide cassettes contained substitutions of the general formula NNK (where N is G, A, T or C and K is either G or C 27 ) at each of the five codons chosen for mutagenesis. Every one of the 20 amino acids usually found in biologically produced proteins can be specified by this approach. These redundant oligonucleotide cassettes were inserted between the unique BstXI and SacI sites of pMON15970 to generate a library (see Figure 1 ).
Analytical affinity experiments to determine library screening conditions
Single-round analytical affinity selection experiments were used to demonstrate presentation of both component cytokine receptor agonist domains of myelopoietin on pMON15970 phage. Polyvalent antibodies were bound to microtiter plates and used to affinity select pMON15970 particles using binding and wash conditions previously described. 1, 14 Myelopoietin-presenting phage were also affinity selected using engineered mammalian cells. Affinity selections for presented hG-CSF receptor agonist domains were performed using BAF-3 cells expressing the hG-CSF receptor (BAF-3/G-CSFR cells 1 ) while selections for the hIL-3 receptor agonist domain was performed using BHK/IL-3R cells.
14 For mammalian cell experiments, phage binding, washing, elution and amplification protocols were as previously described. 14 To demonstrate that presented myelopoietin was in a biologically relevant configuration, single round analytical biopannings were performed on a 500 to 1 input mixture of M13K07 particles (kanamycin resistant, not selected by the affinity reagents) and pMON15970 particles (ampicillin resistant, selected by the affinity reagents). Enrichment for the affinity selected particles (selectants) in these experiments was calculated as the output ratio divided by the input ratio of pMON15970 to M13KO7 particles.
14 That is, the ratio of pMON15970 to M13KO7 particles following affinity selection (the output ratio) divided by the ratio of pMON15970 to M13KO7 particles before affinity selection (the input ratio). The ratios of phage particles were determined from colony counts of transfected E. coli on ampicillin or kanamycin plates.
A multiple round analytical biopanning experiment was used to determine how many rounds of affinity selection were needed to eliminate from the library those phage that do not bind the hG-CSF receptor. A mixed population of particles as described above (mimicking a variant library where most of the variants do not recognize receptor, using 25%/75% phage able/unable to bind) and affinity selected using BAF3/G-CSFR cells (described above) for four rounds, with amplification in E. coli between each round. Samples of DNA (250 ng) were extracted from pools of affinity-selected particles from each round and examined by agarose gel electrophoresis to determine how many rounds of selection were needed before nonbinding phage could no longer be detected in selectant populations. This information was used to identify the round of selection during myelopoietin variant library screening at which we began to choose selectants for expression as individual variant proteins in E. coli.
Affinity screening a display library of myelopoietin variants
The myelopoietin variant library was screened by iterative affinity selection with the mammalian cells expressing the hG-CSF receptor (BAF3/G-CSFR cells, see below). All phage manipulations, affinity and amplification protocols were as previously described. 14 We decided to discontinue affinity screening of the library after of two consecutive rounds of selection in which DNA sequencing revealed that 85% or more of selectants had been identified in previous rounds.
Characterization of selected variant myelopoietin molecules
We used the results of the multi-round analytical affinity experiment (see above) to determine at which round we would begin to isolate and characterize individual selectant clones. In each round in which selectants were examined, Leukemia about 200 randomly chosen isolates were subjected to DNA sequencing. 31 Protein variants expressed from each distinct myelopoietin variant gene were further characterized. Individual variant myelopoietin proteins were produced in E. coli as described 32 and quantitated using a sandwich ELISA for the hIL-3 receptor agonist domain. 1, 14 Quantitation using the hIL-3 agonist domain was chosen to avoid artifacts due to variability in antibody recognition that could potentially occur due to mutagenic changes in the hG-CSF receptor agonist domain. hIL-3-dependent AML193.1.3 14 and hG-CSF-dependent BAF-3-G-CSFR 1 cell proliferation assays were performed as described. All proliferative activity determinations were made in triplicate.
Results
Myelopoietin was presented on phagemid particles and recognized by receptors
The parental myelopoietin species (see Materials and methods) was presented using pMON15970, a 'monovalent' presentation vector (Figure 1 ). Physical linkage of myelopoietin to pMON15970 particles was demonstrated directly by immunoblotting. pMON15970 particles were recognized both by antibodies directed to SC-63032 (the hIL-3 receptor agonist) and to hG-CSF receptor agonist (Figure 2) .
Affinity selection was used to confirm that both receptor agonist domains of myelopoietin were accessible to affinity reagents. Particles derived from pMON15970 were 10 4 -10 5 -fold more efficiently affinity selected with polyclonal antibodies directed to either SC-63032 or hG-CSF than by an (irrelevant) antibody directed to bovine somatotropin (bST, see Table 1 ). In two replications of this experiment, antibodies to the receptor agonist domains affinity selected pMON15970 particles in excess of 10 3 -fold better than did the control irrelevant antibody.
To demonstrate that the presented component proteins of myelopoietin were in a biologically active configuration, pMON15970 particles were selected using cytokine receptors.
14 pMON15970 particles were preferentially selected by cells expressing either the hIL-3 receptor or the hG-CSF receptor (Table 1 ). In three replications of the experiment, enrich-
Figure 2
The hIL-3 and hG-CSF receptor agonist domains of myelopoietin are physically associated with pMON15970 particles. Western blots of non-denaturing agarose gels loaded with M13K07 (not presenting myelopoietin, lanes 1 and 3) and pMON15970 (presenting myelopoietin, lanes 2 and 4) stained with antibodies to the hIL-3 receptor agonist SC63032 (lanes 1 and 2) or to hG-CSF receptor agonist (lanes 3 and 4). Both component agonists (of hIL-3 and hG-CSF receptors) of myelopoietin are presented for affinity selection on pMON15970 particles. Polyclonal antibodies directed to either the hIL-3 receptor agonist module (anti-SC-63032), the hG-CSF receptor agonist module (anti-hG-CSF) of presented myelopoietin, or to neither (antibST), were used as described as affinity reagents. Cells expressing either the hIL-3 receptor (BHK/IL-3R cells 14 ), hG-CSF receptor (BAF-3/G-CSFR cells 1 ) or neither (BAF-3, or BHK cells) were also used for affinity selection of pMON15970. Enrichment was calculated as described 14 from the ratios of pMO15970 (ampicillinresistant) colonies to M13KO7 colonies (kanamycin-resistant) before and after the phage mixture was selected with a given affinity reagent. The fold enrichment figure presented is the ratio of ampicillin resistant to kanamycin resistant colonies after selection with a test affinity reagent (output ratio) divided by the same ratio determined before the phage mixture was exposed to the affinity reagent (input ratio). ment was at least 10 2 -fold better on cells with either receptor than on cells with no receptor expressed on their surfaces. Consistent with previous experience, 14 backgrounds were higher, and the levels of enrichment lower when cells, as opposed to antibodies bound to a plate, were used as affinity reagents.
Thus, both myelopoietin receptor agonists were presented on the surface of pMON15970 particles, and were recognized by their corresponding receptor.
Determining affinity screening conditions
The multi-round analytical affinity experiment showed that control phage that could not bind the hG-CSF receptor were not detected after two rounds of affinity sorting with the receptor. We therefore determined to express and assay the proliferative activity of only myelopoietin variant selectants from our library that were isolated at round two or later of biopanning. To decide when to stop affinity screening of the library (and analysis of selectants), we had decided (arbitrarily) to terminate screening after two consecutive rounds of biopanning in which 85% or more of selectants had been identified in previous rounds. Sequence data (see below) revealed the criterion was met after the sixth round of affinity selection. Therefore, we decided to assay the biological activity of individual variant myelopoietin species of selectants isolated between affinity selection rounds 2 to 6, inclusive.
Characterizing and screening the myelopoietin display library
The myelopoietin phage display library was estimated to encode Ͼ3.44 × 10 5 variant myelopoietin species. Sequence analysis of 10 individual phagemids chosen at random from the starting library revealed codon substitutions at each of the mutagenized positions. Though the mutagenesis design should have excluded A and T at the third position of the codons of the mutagenized positionsm, 27 these nucleotides occasionally occurred at that position (occurring twice among the isolates shown in Table 2 ) and may reflect a minor imperfection in redundant oligonucleotide synthesis.
Over 1000 individual selectants isolated between rounds 2 to 6 of affinity selection with hG-CSF receptor were examined by DNA sequencing. Among these selectants were a total of 130 distinct mutant myelopoietin genes, the remainder being comprised of 'sibling' isolates of the 130 unique isolates (identical at the DNA sequence level). These distinct selectants are summarized in Table 2 . DNA sequence is indicated only when it differentiates otherwise identical isolates.
Affinity screening with the hG-CSF receptor dramatically reduced library complexity. We estimate that in excess of 99.9% of the variants in the input library were not identified as selectants.
Cell proliferative activity of affinity-selected myelopoietin variants
At least one isolate of each distinct variant myelopoietin species was expressed in E. coli, quantitated by ELISA and assayed in a hG-CSF-dependent cell proliferation assay. The mean activity of the selectants increased with the number of rounds of biopanning (data not shown), suggesting that receptor affinity/bioactivity maturation 11, 12, 16 resulted from the affinity selection. The biological activities of the variant myelopoietins were separated into three classes.
Members of the class of highest activity variants were comparable in potency to the parental myelopoietin species (between half and two-fold the potency of the parent myelopoietin species, group A of Table 2 ). Fifty-five such variants were discovered. The second class of 26 intermediate activity variants exhibited moderate but significant reductions in activity (two-to 10-fold less potent than the parental molecule, group B, Table 2 ). A large group (group C of Table 2 , 49 of 130 selectant species) of low activity variants (у10-fold less potent) were also isolated.
Notably, no variant isolated had significantly improved proliferative activity (Ͼtwo-fold more potent) relative to the parental myelopoietin species in the hG-CSF assay.
Sequence analysis of affinity-selected myelopoietin variants
Display experiments typically select consensus protein sequences, corresponding to variant polypeptides with similar (though not necessarily identical) amino acid substitutions encoded by distinct nucleotide sequences. Their distinct nucleotide sequences demonstrate that members of a consensus are not siblings, and are separate selectants. They represent solutions to the binding problem posed in the affinity selection that are good enough to have been independently selected multiple times.
A protein sequence consensus emerged among the high activity variants (group A), derived from six consensus groups of highly similar phage (Table 2) . Within each consensus group the specified variant myelopoietin species were identical, though their DNA sequences were distinct, indicating they were independent affinity selectants and not siblings. 43X  44P  49L  52X  K40R  H43S  P44A  H52D  H43K  L49F  H52N  K40G  H43R  P44V  H52R  H43R  L49V  H52G  K40G  H43G  P44S  H52N  H43R  L49K  H52Q  K40G  H43S  P44A  H52V  H43R  L49M  H52N  K40G  H43S  P44V  H52V  H43R  L49M  K40Q  H43T  P44E  H52G  H43R  H52F  K40S  P44E  H52D  H43L  L49Y  H52K  K40S  H43S  H52A  H43L  L49Y  H52Q  K40S  H52K  H43E  L49W  H52M  K40L  H43S  P44E  H52A  H43G  L49S  H43Y  L49W  H52M  H43S H43R  P44  L49S  H52R  H43K  L49R  H43S  L49H  H52R  L49W  H52R  H43R  H49K  H52T  H43R  H49T  H52Q  H43R  L49S  H52N  H43R  H52P  H43A  L49T  H43G  L49H  H52S  H43G  H52Q  H43G  H52E  H43V  L49Q  H52W  H43S  H52S  H43S  L49F  H52K  H43F  L49R  H52D  K40G  H52E  K40S  H43R  H52K  K40S  H43V  H52S  L49V  L49Y  H52R  H43S  L49Y  H52T  K40G  H43R  H52A  K40S  H43A  P44H  H52R  K40S H43S H52G H43D  P44  L49T  H52P  K40R  H43S  H52K  H43K  L49R  H52R  K40L  H52K  H43K  L49W  H52S  K40L  H43A  H52R  H43K  H52S  K40G  H43S  H43T  L49N  H52R  K40G  H43V  H52K  H43T  L49P  H52Q  K40G  H52E  H43R  L49I  H52S  K40S  H43L  H52L  H43R  L49F  H52R  K40S  H43Q  H52Q  H43R  L49E  H52P  H43S  H52A  H43S  L49N  H52R  P44K  L49A  H52P  H43R  L49E  H52N  L49A  H52N  H43R  L49T  L49N  H52E  H43R  L49I  H52K  H43D  L49T  H52P  H43R  L49Q  H52S  H43S  H52A  H43L  L49N  H52Q  K40V  H43R  P44T  H52E  H43E  L49I  H52I  K40V  H43L  P44L  H52D  H43D  L49M  H52N  H43G  L49N  H52T  H43G  L49P  H52S  H43G  L49A  H52M  H43V  L49T  H52T  H43S  L49N  H52V  H43S  L49M  H52T  H43S  L49H  H52I  H43S  L49K  H52R  H43S  L49N  H52N  H43S  L49N  H52I  H43S  L49T  H52R  H43L  L49Q  H52S  H43F L49S H52G
Affinity-selected myelopoietin variants fall into three groups: high proliferative activity (half to twice as active as the parent, group A), intermediate proliferative activity (1/10 to half as active as parent, group B), and low proliferative activity (less than 1/10 as active as parent). DNA sequence, as well as activity, in a hG-CSF-dependent cell proliferation assay of individual variant myelopoietin species identified from affinity-selected particles (using BAF-3/G-CSFR cells) and expressed in E. coli was determined (see Materials and methods). The amino acid residue numbering scheme used for the hG-CSF receptor agonist module of presented myelopoietin is the same as that used for parental hG-CSF (Refs 20-25, see Materials and methods). Amino acid identity is indicated using the single letter code, and codon usage is indicated only when it differentiates otherwise identical isolates. With that exception, substitution with the parental amino acid is indicated by a blank. Consensus groups are comprised of phage with identical amino acid sequences but distinct nucleotide sequences, and occur most frequently among high activity selectants (group A). Consensus groups are indicated at the beginning of each section. Consensus sequences are derived from consensus groups, and indicate the similarities in sequence observed between consensus groups. Consensus sequences are indicated in bold after the consensus groups in each section. In the group A consensus sequence, X indicates substitution with one of the following hydrophilic amino acids: G, S, T,Y, Q, D or E.
Only one consensus group each were found for groups B and C ( Table 2 ). The amino acid substitutions identified in the 55 high activity variants (group A) are summarized by chemical class in Table 3 . Much of the data is consistent with previous studies of mutagenesis of surface residues, 26, 27 and with structural and genetic studies of hG-CSF variants specifically.
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Discussion
The myelopoietin library was large (compared to those used in conventional mutagenesis, see Ref. 29 ), containing Ͼ10 5 mutant genes, but it did not contain all variants that could have been specified by the mutagenic strategy. 11, 12 It was successfully affinity screened: hG-CSF activity of the affinityselected variants increased and diversity of selected phage populations decreased with iterative rounds of selection. Consensus protein sequences were identified among high activity variants, where six similar consensus groups emerged (Table 2) . These sequences are similar to parental sequences: for our assays, parental sequence may be optimal at the mutagenized sites. No selectants had better proliferative activity, despite the importance of the mutagenized region for hG-CSF function. [20] [21] [22] [23] [24] [25] The data suggest that display artifacts 11, 12, 14, 30 may have been operative in our experiments: parental myelopoietin could have been specified in our library (see Materials and methods), is presented on phage, and recognizes hG-CSF receptor (Figures 1 and 2 , and Table 1 ), but it was not isolated ( Table 2 ). Clearly then, we did not identify all active variants that could have been in the library. Also, since multiple sites were mutagenized, the effect of individual substitutions is unclear in most cases. Still, analysis of high activity variant sequences was consistent with, and extends previous studies of hG-CSF (Table 3, Refs 22 and 23) .
While display is a powerful method to engineer maximal affinity of a protein for a counter-receptor, 11 ,12,33-37 it may be less suited to engineer bioactivity properties of growth factors. High affinity may be necessary, but not sufficient, to maximize activity, 28 and other physiological or biochemical processes which are not addressed by affinity selection, may be key determinants of cytokine activity once affinity requirements are fulfilled. Our screening strategy for myelopoietin variants took these considerations into account.
The highest affinity variants may not be the most active, so we configured our affinity screen to maximize isolation of variants that bound receptor and then screened all such selectants without bias. We began proliferation studies immediately after elimination of non-binding variants (after round 2 of selection) and continued selection until library diversity was nearly exhausted (only about 5% of variants were previously unidentified at round 6). This is a labor-intensive response to non-linear affinity/activity correlations. We characterized over 1000 variants, most of which were siblings of others in the collection. Despite the inclusive approach to affinity screening, we did not identify variants with significantly enhanced proliferative activity.
Failure to identify myelopoietin species with enhanced hG-CSF receptor agonist activity is superficially similar to the hGH case. 28 In that case and others, 38 the parent molecule has receptor affinity higher than needed to drive maximal proliferation, and does not exhibit maximal receptor affinity possible for hGH variants: no higher affinity variant identified using display had improved potency. Do these results discredit display for engineering higher potency cytokines? The data do not warrant that conclusion.
First, multiple growth factor variants with better activity than their parents have been identified using display mutagenesis. 19, 39 Second, the myelopoietin group A consensus sequence is identical to the parent sequence at 40, 44 and 49 ( Table 2 ), suggesting that the specific parental amino acid sequences at these positions may be optimal for activity in our hG-CSF proliferation assay, and that lack of myelopoietin variants with better agonist activity may not be related to a non-linear relationship between affinity/agonist activity. If other positions been mutagenized, myelopoietin variants with enhanced hG-CSF receptor agonist activity might have been identified.
Third, there are other growth factors that have not been engineered by display, but are good candidates for the approach. Active hIL-3 variants can be presented on phage, 14, 15 and hIL-3 variants with 10-fold increased proliferative activity isolated by conventional mutagenesis have 20-fold enhanced affinity for the receptor complex. 32, 40 Thus, display of native hIL-3 on phage is feasible, affinity maturation for the receptor complex could have identified variants with better agonist activities. There may be other cytokines, some perhaps unknown, that could be productively affinity matured.
Thus display-based maturation of receptor affinity is applicable to engineering some, 19, 39 but not all, 34 protein hormones for enhanced activity. Also, affinity screening of peptide libraries on phage can identify novel peptidic agonists of cytokine receptors. [38] [39] [40] [41] [42] [43] Maturation of the affinity of a polypeptide for a receptor to enhance its potency is applicable if its agonist activity is limited by its affinity for that receptor. This can be assumed when screening a random peptide library, but it is not a priori obvious whether any given native protein hormone is so limited: the fact has to be determined empirically. Also, the 'right' amino acid positions must be mutagenized to generate improved variants. Those positions must also be identified empirically.
Leukemia
For cytokine variants used ex vivo or in vivo, engineering issues are even more complex. For instance, chimera receptor agonist activity is influenced (qualitatively and quantitatively) by density and distribution of receptors of responder cells, other diffusible factors, and other cells in the proliferative environment. Thus, in vitro proliferation assays might rank therapeutic candidates easily, but are only an initial screen. Other factors (host responses, clearance, biodistribution, etc) influence efficacy and must be evaluated to support in vivo use of engineered variants. If such factors are influenced by cytokine amino acid sequence they might be addressed by mutagenesis, but using display to select these properties, while also selecting high-affinity variants, is challenging.
Demonstrating feasibility and applying display-based affinity maturation to a cytokine-receptor system takes substantial work. The methods' most reliable use for engineering protein hormones may be to make collections of variants with similar bioactivities that can then be screened for other properties (physical properties such as stability or biological properties like qualitative differences in differentiation induced by variants, biodistribution or pharmacokinetic properties). Display can additionally provide genetic data. Substitutions of high activity myelopoietin variants are discussed below.
hG-CSF positions 40 and 49 may be site 1 receptor contact residues. 22 Position 40 showed strong bias toward hydrophilic residues (47/55 variants, Table 3 ) and frequently contained parental lysine (31/55 isolates), though other hydrophilic residues also occurred. The importance of position 40 is debatable. It may be a receptor contact for hG-CSF bound to the murine receptor, as it is reported to be intolerant of hydrophobic substitution in that context, 22 though alanine substitution does not affect binding to human receptor. 23 We also found hydrophobic amino acids at 40 occasionally (8/55, Table 3 ). Position 49 may be less ambiguously a receptor contact. 22 Most high activity variants had parental leucine (36/55, Table 3 ) or were conservatively substituted by other hydrophobic amino acids here. Six high activity isolates with hydrophilic substitutions at 49 were also isolated (Table 3) .
High activity variants most often had parental proline at position 44 (47/55, Table 3 ), though other hydrophobic residues occurred, and hydrophilic amino acid substitutions Amino acid prevalence among high activity selectants (Table 2) Table 2 and text).
Leukemia (4/55) were rare. The position is not a predicted receptor contact, 22 but bias favoring the parental residue at 44 was more profound than at putative contact positions 40 or 49.
Amino acid preference in high activity variants at positions 43 and 52 were alike (Table 3) . Substitutions were conservative (mostly hydrophilic), though there was not profound bias favoring parental histidine (Table 3) . Hydrophobic substitutions were observed infrequently (4/55 at 43, and 8/55 at 52, Table 3 ), despite the fact that alanine substitution is well tolerated at both positions. 21, 22 Preference for the parental substitutions at 40 and 49 can be rationalized if they are, as speculated, receptor contact residues. 22 The data also suggest an unexplained, but important role for the proline at position 44 that had not been tested in other hG-CSF studies. Positions 43 and 52 behaved as 'low information content residues', 23, 24 wherein hydrophilic amino acid substitution had small impact on bioactivity.
Conclusions and prospects
Myelopoietin is the first chimeric protein to be presented and mutagenized on phage, except perhaps, single-chain Fv antibody fragments (ScFvs, consisting of the variable heavy or V H and variable light or V L domains of antibodies linked by a flexible peptide, [34] [35] [36] [37] ). ScFvs are chimeric proteins, though we view them as a special case. The V H and V L domains constituting ScFvs have been selected by evolution to be efficiently co-expressed, secreted and assembled into a single molecule, and to perform, as a unit, a single recognition function. This is not true of myelopoietin molecules as the activities of the component receptor agonists are distinct, result from engagement of different receptors, and are not known to co-reside in any naturally occurring protein. They exhibit novel and desirable biological properties when they are combined into single myelopoietin molecules, 1, 10 making myelopoietin molecules more typical of purpose-designed chimeric proteins.
Each domain of a chimeric protein contributes to overall activity, potentially necessitating adjustment of the properties of constituent proteins to optimize the chimera.
Steric interactions can interfere with activities of chimera components. [44] [45] [46] Physical and chemical properties of individual protein components might differ, making it desirable to make components of chimeras compatible in their expression, purification and stability properties to simplify production. Chimeras might exhibit poor pharmacokinetic-biodistribution characteristics, resulting from either properties of constituent domains, or linking constitutent domains together. Mutagenesis, [47] [48] [49] [50] or other modifications of primary amino acid sequence [44] [45] [46] can address these issues. Engineering chimeras as a unit rather than engineering functional domains individually reduces the potential for surprise when engineered functional domains are re-united after mutagenesis. We isolated a selection of myelopoietin variants with a wide range of hG-CSF agonist potencies that may be screened subsequently for other properties of interest. Thus, even when display technology does not identify more potent variants, the technique can be useful to adjust the contribution of each component to overall activity. Within its limitations (Refs 28, 34 and this work), phage display is applicable to efficient mutagenesis of chimeric cytokines, and potentially other chimeric proteins as well.
